enprofylline has been researched along with Contact Dermatitis in 2 studies
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Solinski, HJ | 1 |
Dranchak, P | 1 |
Oliphant, E | 1 |
Gu, X | 1 |
Earnest, TW | 1 |
Braisted, J | 1 |
Inglese, J | 1 |
Hoon, MA | 1 |
Zunich, KM | 1 |
Nelson, HS | 1 |
Patel, A | 1 |
Bodman, S | 1 |
Gilner, D | 1 |
Winder, J | 1 |
1 trial available for enprofylline and Contact Dermatitis
Article | Year |
---|---|
The effect of theophylline and enprofylline on the late cutaneous response to antigen and compound 48/80.
Topics: Adult; Antigens; Dermatitis, Contact; Double-Blind Method; Humans; Hypersensitivity, Immediate; p-Me | 1989 |
1 other study available for enprofylline and Contact Dermatitis
Article | Year |
---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |